We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... than a fifth of their body weight. The phase 3b STEP UP trial in more than 1,400 patients compared ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...

Last week, Novo Nordisk released headline results from the STEP UP Phase 3b trial in the global STEP program. When evaluating the effects of treatment if all people adhered to treatment from a ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Democratic Republic of Congo authorities are investigating 12 possible cases of the deadly Ebola virus in its northwest, ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...